Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumorsAlison M. Schram, Jayesh Desai, Jia‐Rong Chen et al.|Cancer Research|2023Cited by 12